FDA Considers Incorporating Patient Input In Generic Drug Assessments

US Agency Mulls Changes But Acknowledges Challenges For Off-Patent Medicines

The popular patient-focused drug development model for new drugs might not fit for generics, in part because the affected patient groups would be much larger.

Sign outside of FDA's headquarters in White Oak, MD
Patient influence at the FDA could increase if patient input is allowed to influence generic drug decisions

More from Regulation

More from Policy & Regulation